Last reviewed · How we verify
NCT04363047
Immune Cells in Inflammatory Arthritis With Coronaviruses, Including COVID-19
trial testing 40ml blood sample in SARS Virus in 125 participants. Enrolling by invitation.
31 July 2026
Quick facts
| Lead sponsor | University of Manchester |
|---|---|
| Status | ENROLLING BY INVITATION |
| Study type | OBSERVATIONAL |
| Enrollment | 125 |
| Start date | 1 October 2020 |
| Primary completion | 31 July 2026 |
| Estimated completion | 31 July 2026 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- 40ml blood sample
Conditions studied
- SARS Virus — all drugs for SARS Virus →
Sponsor
University of Manchester
Who can join
18 and older, any sex, with SARS Virus. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A team at the University of Manchester are developing a test that tcould be helpful in detecting immunity to the Coronavirus (which causes the COVID-19 disease) in participants with inflammatory arthritis. It is based on a flu assay has already developed; the team will replace the flu antigen with a Coronavirus antigen to see if it is effective. This project aims to develop a test to see if people who have had the virus have developed immunity to it. This could help to predict who might or might not get the disease a second time, who should stay at home to be protected from potential infection or who will not develop any symptoms, even if exposed to the virus. When vaccination trials against the Coronavirus will be launched, this test could also help to see if the vaccine is effective.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04363047
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other University of Manchester trials
Trials by the same sponsor.
- NCT07506096 — Using IF-THEN Plans to Support Healthcare Professionals in Raising Patient Safety Concerns · NA · not yet recruiting
- NCT07084090 — Using IF-THEN Plans to Support Patients in Raising Safety Concerns About Their Care · NA · not yet recruiting
- NCT07494760 — A Feasibility Randomised Control Trial to Evaluate Early Perinatal Bereavement Counselling for Parents Who Have Experien · NA · not yet recruiting
- NCT07372885 — GRanulocyte Augmented Cord Blood Transplantation for Poor Risk leukaEmia · Phase 1, PHASE2 · not yet recruiting
- NCT07381894 — Multicentre Hypertrophic Cardiomyopathy Registry · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04363047 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Manchester
- Last refreshed: 8 May 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04363047.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing